Xeris Biopharma Holdings
Income Statement

Last updated:

Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. Xeris Biopharma Holdings's past years’ income statements indicate that its last revenue has increased compared to the previous period by 447% to $110,248,000. Profit margin reached -86%. Total operating expenses were $169,554,000.

Profit Margin

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS): Profit margin
2016 1.07M -13.20M -1228.74%
2019 20.15M -91.14M -452.2%
2022 110.24M -94.66M -85.86%

XERS Income Statement (2017 – 2023)

2023 2020 2017
Revenue
Revenue
110.24M20.15M1.07M
Cost of revenue
22.63M9.32M8K
Gross profit
87.61M10.82M1.06M
Operating exp.
Research and development
20.96M20.92M10.23M
Selling and marketing
000
Total operating expenses
169.55M94.37M14.29M
Operating income
-81.94M-83.54M-13.23M
Other income (expenses), net
-14.14M-3.65M22K
Income before tax
-96.08M-91.25M-13.20M
Income tax expense
-1.42M-110K-3K
Net income
-94.66M-91.14M-13.20M
Earnings per share
Basic EPS
-0.7-3.49-7.17
Diluted EPS
-0.7-3.49-7.17
Data source